Trial reportMolecular imaging and biology2016
Human Radiation Dosimetry of [(18)F]AV-1451(T807) to Detect Tau Pathology.
Trial report in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Cyclic 2.5D Perceptual Loss for Cross-Modal 3D Medical Image Synthesis: T1w MRI to Tau PET.Human brain mapping · 2026Article
- Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review.Brain sciences · 2025Review
- Human biodistribution and radiation dosimetry of two novel α-synuclein PET tracers,Scientific reports · 2025Article
- Human biodistribution and radiation dosimetry for the tau tracer [EJNMMI radiopharmacy and chemistry · 2024Article
- Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects.Annals of nuclear medicine · 2023Article
- Dosimetry and efficacy of a tau PET tracer [Annals of nuclear medicine · 2023Article
- A Brief History of Nuclear Medicine Physics, Instrumentation, and Data Sciences in Korea.Nuclear medicine and molecular imaging · 2021Review
- Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [Frontiers in bioengineering and biotechnology · 2021Article
- Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC).EJNMMI radiopharmacy and chemistry · 2020Article
- Preclinical Safety Evaluation and Human Dosimetry of [Molecular imaging and biology · 2020Article
- Article
- An updated radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[(18)F]AV-1451 is a positron emission tomography (PET) radioligand for detecting paired helical filament tau. Our aim was to estimate the radiation dose of [(18)F]AV-1451 in humans. PROCEDURES: Whole-body PET scans were acquired for six healthy volunteers (three male, three female) for 128 min after injection of [(18)F]AV-1451 (268 ± 31 MBq). Radiation doses were estimated using the OLINDA/EXM software.
resultsThe estimated organ doses ranged from 7.81 to 81.2 μSv/MBq. The critical organ for radiation burden was the liver. Radiation doses to the reproductive and blood-forming organs were 14.15, 8.43, and 18.35 μSv/MBq for the ovaries, testes, and red marrow, respectively. The mean effective dose was 22.47 ± 3.59 μSv/MBq.
conclusionsA standard single injection of 185 MBq (5 mCi) results in an effective dose of 4.7 mSv in a healthy subject. Therefore, [(18)F]AV-1451 could be used in multiple PET scans of the same subject per year.
Indexed as
Identifiers
26728162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.